The first Transatlantic Taskforce on Antimicrobial Resistance (TATFAR) progress report was released on Tuesday by the U.S. Department of Health and Human Services (HHS) and the European Commission.
During its first implementation period between 2011-2013, TATFAR adopted procedures for the U.S. and Europe to exchange information regarding new antimicrobial resistance trends that could have public health implications. Joint presentations were also made to the scientific community about funding opportunities on both sides of the Atlantic, and a report on a 2011 workshop studying new diagnostic testing methods was published on the TATFAR website.
"The partnership offers a unique perspective to tackle antimicrobial resistance worldwide," Jimmy Kolker, the assistant secretary for global affairs at the HHS, said. "We hope that the positive outcomes of this partnership will serve as a global model as we continue to work on this critical issue."
Fifteen o f the 17 areas of collaboration between the U.S. and EU in the first implementation period will carry over into the 2014-2016 period, including one new recommendation.
TATFAR was created in 2009 after the U.S.-EU presidential summit in order to improve cooperation in using antimicrobrial drugs appropriately in the medical community, preventing healthcare-related infections and improving the pipeline for new medications.
The European Centre for Disease Prevention and Control served as the TATFAR secretariat during the first implementation period. The CDC will take over for the 2014-2016 session.